Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo.

Lysophosphatidic acid (LPA) is elevated in ascites of ovarian cancer patients and stimulates growth and other activities of ovarian cancer cells in vitro. Tissue hypoxia is a critical factor for tumor aggressiveness and metastasis in cancers. We tested whether the ascites of ovarian cancer is hypoxic and whether hypoxia influences the effects of LPA on ovarian cancer cells. We found that ovarian ascitic fluids were hypoxic in vivo. Enhanced cellular responsiveness to LPA, including migration and/or invasion of ovarian cancer cells, was observed under hypoxic conditions. This enhancement could be completely blocked by geldanamycin or a small interfering RNA targeting hypoxia-inducible factor 1 alpha (HIF1 alpha). LPA-induced cell migration required cytosolic phospholipase A(2) (cPLA(2)) and LPA stimulates cPLA(2) phosphorylation in a HIF1 alpha-dependent manner under hypoxia conditions. Furthermore, we show for the first time that exogenous LPA enhances tumor metastasis in an orthotopic ovarian cancer model and HIF alpha expression in tumors. 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (an inhibitor of the heat shock protein 90) effectively blocked LPA-induced tumor metastasis in vivo. Together, our data indicate that hypoxic conditions are likely to be pathologically important for ovarian cancer development. HIF1 alpha plays a critical role in enhancing and/or sensitizing the role of LPA on cell migration and invasion under hypoxic conditions, where cPLA(2) is required for LPA-induced cell migration.

[1]  P. O'dwyer,et al.  Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. , 1999, Cancer research.

[2]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[3]  G. Mills,et al.  Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells* , 2004, Journal of Biological Chemistry.

[4]  G. Mills,et al.  Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  K. Malik,et al.  Norepinephrine-Induced Stimulation of p38 Mitogen-Activated Protein Kinase Is Mediated by Arachidonic Acid Metabolites Generated by Activation of Cytosolic Phospholipase A2 in Vascular Smooth Muscle Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[6]  Yan Xu,et al.  Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. , 2001, Analytical biochemistry.

[7]  M. Murakami.  Hot topics in phospholipase A2 field. , 2004, Biological & pharmaceutical bulletin.

[8]  J. Knisely,et al.  Importance of hypoxia in the biology and treatment of brain tumors. , 2002, Neuroimaging clinics of North America.

[9]  Zeneng Wang,et al.  Biology of LPA in health and disease. , 2004, Seminars in cell & developmental biology.

[10]  G. Mills,et al.  Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  G. Mills,et al.  Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  O. Lesur,et al.  Clara cell protein (CC-16) induces a phospholipase A2-mediated inhibition of fibroblast migration in vitro. , 1995, American journal of respiratory and critical care medicine.

[13]  E. Sausville,et al.  In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative , 2005, Cancer Chemotherapy and Pharmacology.

[14]  H. Stettner,et al.  The spread of ovarian cancer. , 1989, Bailliere's clinical obstetrics and gynaecology.

[15]  L. Baudhuin,et al.  Role of ether-linked lysophosphatidic acids in ovarian cancer cells. , 2002, Journal of lipid research.

[16]  H. Stettner,et al.  1 The spread of ovarian cancer , 1989 .

[17]  M. Quintero,et al.  Hypoxia-inducible factor 1 (HIF-1) in cancer. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  G. Mills,et al.  In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  Yan Xu,et al.  Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. , 2001, Gynecologic oncology.

[20]  E. Kohn,et al.  Angiogenesis in ovarian cancer. , 2000, Bailliere's best practice & research. Clinical obstetrics & gynaecology.

[21]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[22]  Y Chen,et al.  Evaluation of Plasma Lysophospholipids for Diagnostic Significance Using Electrospray Ionization Mass Spectrometry (ESI‐MS) Analyses , 2000, Annals of the New York Academy of Sciences.

[23]  R. Bast,et al.  Pathogenesis of Ovarian Cancers , 1994, The Journal of the Society for Gynecologic Investigation: JSGI.

[24]  L. Repesh.  A new in vitro assay for quantitating tumor cell invasion. , 1989, Invasion & metastasis.

[25]  Robert M Hoffman,et al.  A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer , 1998, Clinical & Experimental Metastasis.

[26]  G. Turner,et al.  Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. , 1995, Cancer letters.

[27]  M. Jaye,et al.  Activation of Cytosolic Phospholipase A by Basic Fibroblast Growth Factor via a p42 Mitogen-activated Protein Kinase-dependent Phosphorylation Pathway in Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.

[28]  G. Mills,et al.  The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.

[29]  G. Mills,et al.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. , 2001, Journal of the National Cancer Institute.

[30]  Yan Xu,et al.  A novel laminin‐induced lysophosphatidic acid autocrine loop in the migration of ovarian cancer cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  P. Allavena,et al.  Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy , 1989, International journal of cancer.

[32]  L. Baudhuin,et al.  The Role and Clinical Applications of Bioactive Lysolipids in Ovarian Cancer , 2001, The Journal of the Society for Gynecologic Investigation: JSGI.

[33]  Erwin G. Van Meir,et al.  Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. , 2002, Cancer research.

[34]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[35]  E. Kohn,et al.  Promising directions for the diagnosis and management of gynecological cancers , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[36]  Repesh La.  A new in vitro assay for quantitating tumor cell invasion. , 1989 .

[37]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[38]  Nagadhara Dronadula,et al.  STAT-3-dependent Cytosolic Phospholipase A2 Expression Is Required for Thrombin-induced Vascular Smooth Muscle Cell Motility* , 2005, Journal of Biological Chemistry.

[39]  Li Feng,et al.  Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. , 2006, Cancer research.

[40]  Daniel L Baker,et al.  Plasma lysophosphatidic acid concentration and ovarian cancer. , 2002, JAMA.

[41]  E. Goetzl,et al.  Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2) , 2004, Oncogene.

[42]  R. Gertz,et al.  The significance of urokinase‐type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer , 1995, Cancer.

[43]  D. Schrump,et al.  Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. , 2000, The Annals of thoracic surgery.

[44]  B. Karlan,et al.  Genetic aspects of ovarian cancer , 1994, Current Opinion in Obstetrics and Gynecology.

[45]  G. Mills,et al.  Lysophospholipids activate ovarian and breast cancer cells. , 1995, The Biochemical journal.

[46]  G. Mills,et al.  Specific keynote: molecular therapeutics in ovarian cancer. , 2003, Gynecologic oncology.

[47]  F. Tremblay,et al.  Sphingosine 1‐phosphate effect on endothelial cell PAF synthesis: Role in cellular migration , 2003, Journal of cellular biochemistry.

[48]  A. Somlyo,et al.  VASCULAR SMOOTH MUSCLE , 1968 .